Dr. Reddy's Laboratories Ltd. (RDY)

37.72
0.60 1.57
NYSE : Health Technology
Prev Close 38.32
Open 38.01
Day Low/High 37.70 / 38.04
52 Wk Low/High 29.00 / 42.82
Volume 68.97K
Avg Volume 155.90K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 6.39B
EPS 1.60
P/E Ratio 23.37
Div & Yield 0.29 (0.71%)
New Lifetime High For Dr Reddy Laboratories (RDY)

New Lifetime High For Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's Q1 FY16 Financial Results

Dr. Reddy's Q1 FY16 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q1FY16 Results On July 30, 2015 // Earnings Call Slated For July 30, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's To Release Q1FY16 Results On July 30, 2015 // Earnings Call Slated For July 30, 6.30 PM IST / 9.00 AM EDT

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the First Quarter ended June 30, 2015 on Thursday, July 30, 2015 after the Board Meeting.

New Lifetime High For Dr Reddy Laboratories (RDY)

New Lifetime High For Dr Reddy Laboratories (RDY)

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's Announces The Launch Of MEMANTINE HYDROCHLORIDE TABLETS, USP

Dr. Reddy's Announces The Launch Of MEMANTINE HYDROCHLORIDE TABLETS, USP

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Memantine hydrochloride tablets USP, 5 mg and 10 mg, a therapeutic equivalent generic version of NAMENDA® (memantine HCl) tablets in the US...

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: CHW, CEN, RDY

Ex-Dividend Alert: 3 Stocks Going Ex-Dividend Tomorrow: CHW, CEN, RDY

CHW CEN RDY are going ex-dividend tomorrow, Wednesday, July 08, 2015

Dr. Reddy's Unveils New Corporate Brand Identity

Dr. Reddy's Unveils New Corporate Brand Identity

Dr. Reddy's Laboratories (NYSE: RDY) today announced the launch of its new visual identity and brand, that will guide its actions across the globe: Good Health Can't Wait.

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Dr. Reddy's Laboratories Limited (NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2015, was filed with the United...

3 Stocks Boosting The Drugs Industry Higher

3 Stocks Boosting The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Dr. Reddy's Q4 & FY15 Financial Results

Dr. Reddy's Q4 & FY15 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q4 And Full Year FY15 Results On May 12, 2015

Dr. Reddy's To Release Q4 And Full Year FY15 Results On May 12, 2015

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Fourth Quarter and Full Year ended March 31, 2015 on Tuesday, May 12, 2015 after the Board Meeting.

Dr Reddy Laboratories (RDY) Weak On High Volume

Dr Reddy Laboratories (RDY) Weak On High Volume

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a weak on high relative volume candidate

3 Large-Cap Pharmaceutical Companies to Invest in Right Now

3 Large-Cap Pharmaceutical Companies to Invest in Right Now

Pharmaceutical companies can be a huge risk for investors -- but if the risks pay off, the rewards can be huge.

Dr. Reddy's Laboratories And Its Subsidiary Promius PharmaTM Announce The Filing Of Three NDAs With The USFDA

Dr. Reddy's Laboratories And Its Subsidiary Promius PharmaTM Announce The Filing Of Three NDAs With The USFDA

Dr. Reddy's Laboratories (NYSE:RDY) and its subsidiary, Promius Pharma™, LLC today announced the filing of three 505(b)(2) New Drug Applications (NDAs) with the U.

Today Dr Reddy Laboratories (RDY) Hits New Lifetime High

Today Dr Reddy Laboratories (RDY) Hits New Lifetime High

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's Laboratories To Acquire Select Portfolio Of The Established Products Business Of UCB In India

Dr. Reddy's Laboratories To Acquire Select Portfolio Of The Established Products Business Of UCB In India

Dr. Reddy's Laboratories today announced that it has entered into a definitive agreement to acquire a select portfolio of the established products business of UCB, in the territories of India, Nepal, Sri Lanka and Maldives.

3 Stocks Moving The Health Care Sector Upward

3 Stocks Moving The Health Care Sector Upward

TheStreet highlights 3 stocks pushing the health care sector higher today.

Dr Reddy Laboratories (RDY) Flagged As Strong On High Volume

Dr Reddy Laboratories (RDY) Flagged As Strong On High Volume

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a strong on high relative volume candidate

Toxic Stocks: It's Time to Sell These 5 Blue-Chip Laggards

Toxic Stocks: It's Time to Sell These 5 Blue-Chip Laggards

With the market making all-time highs, it's time to ditch these underperformers.

Dr. Reddy's (RDY) Stock Gained Today on Earnings Beat

Dr. Reddy's (RDY) Stock Gained Today on Earnings Beat

Dr. Reddy's (RDY) shares were up today after the company reported third quarter results that beat analysts' guidance.

Dr. Reddy's Q3 And 9 Months FY15 Financial Results

Dr. Reddy's Q3 And 9 Months FY15 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's To Release Q3 FY15 Results On January 29, 2015

Dr. Reddy's To Release Q3 FY15 Results On January 29, 2015

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Third Quarter ended December 31, 2014 on Thursday, January 29, 2015 after the Board Meeting.

Dr. Reddy's Laboratories Closes The Acquisition Of Habitrol® Brand From Novartis

Dr. Reddy's Laboratories Closes The Acquisition Of Habitrol® Brand From Novartis

Dr. Reddy's Laboratories has announced that it has closed the acquisition of Habitrol® brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc.

Dr. Reddy's Announces The Launch Of Valganciclovir Tablets, USP

Dr. Reddy's Announces The Launch Of Valganciclovir Tablets, USP

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE ® (Valganciclovir) tablets in the US market on December...

Today Dr Reddy Laboratories (RDY) Hits New Lifetime High

Today Dr Reddy Laboratories (RDY) Hits New Lifetime High

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's Announces The Launch Of Docetaxel Injection USP

Dr. Reddy's Announces The Launch Of Docetaxel Injection USP

Dr. Reddy's Laboratories (NYSE: RDY) announced today that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE ® (docetaxel Injection) in the US...

Dr. Reddy's Announces The Launch Of Over-the-Counter Fexofenadine Hydrochloride 60 Mg And Pseudoephedrine Hydrochloride 120 Mg Extended-Release Tablets

Dr. Reddy's Announces The Launch Of Over-the-Counter Fexofenadine Hydrochloride 60 Mg And Pseudoephedrine Hydrochloride 120 Mg Extended-Release Tablets

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg / 120 mg, a bioequivalent...

3 Drugs Stocks Pushing The Industry Higher

3 Drugs Stocks Pushing The Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Today Dr Reddy Laboratories (RDY) Hits New Lifetime High

Today Dr Reddy Laboratories (RDY) Hits New Lifetime High

Trade-Ideas LLC identified Dr Reddy Laboratories (RDY) as a new lifetime high candidate

Dr. Reddy's Q2 And H1 FY15 Financial Results

Dr. Reddy's Q2 And H1 FY15 Financial Results

Dr. Reddy's Laboratories Ltd.

TheStreet Quant Rating: C (Hold)